ERBB2 and breast cancer: Ultimately, SG was approved for patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer who received endocrine-based therapy and at least two additional chemotherapies in the metastatic setting, expanding its indication and use.